Department of Microbiology & Immunology, Weill Cornell Medicine, New York, New York 10065, United States.
ACS Infect Dis. 2021 Aug 13;7(8):2277-2284. doi: 10.1021/acsinfecdis.0c00853. Epub 2021 Feb 18.
Babesiosis is a tick-borne parasitic disease of humans and livestock that has dramatically increased in frequency and geographical range over the past few decades. Infection of cattle often causes large economic losses, and human infection can be fatal in immunocompromised patients. Unlike for malaria, another disease caused by hemoprotozoan parasites, limited treatment options exist for infections. As epigenetic regulation is a promising target for new antiparasitic drugs, we screened 324 epigenetic inhibitors against blood stages and identified 75 (23%) and 17 (5%) compounds that displayed ≥90% inhibition at 10 and 1 μM, respectively, including over a dozen compounds with activity in the low nanomolar range. We observed differential activity of some inhibitor classes against and parasites and identified pairs of compounds with a high difference in activity despite a high similarity in chemical structure, highlighting new insights into the development of epigenetic inhibitors as antiparasitic drugs.
巴贝斯虫病是一种由蜱传播的寄生虫病,影响人类和家畜。在过去几十年中,它的发病率和地理范围都显著增加。牛感染该病通常会造成巨大的经济损失,而免疫功能低下的患者感染该病可能是致命的。与由血原虫寄生虫引起的另一种疾病疟疾不同,针对 感染的治疗选择有限。由于表观遗传调控是一种有前途的新型抗寄生虫药物靶点,我们筛选了 324 种表观遗传抑制剂来针对 血阶段,并发现了 75(23%)和 17(5%)种化合物,它们在 10 和 1 μM 时的抑制率分别达到了≥90%,其中包括十几个具有低纳摩尔范围活性的化合物。我们观察到一些抑制剂类别对 和 寄生虫的活性存在差异,并确定了尽管化学结构高度相似,但活性差异很大的化合物对,这突显了在开发作为抗寄生虫药物的表观遗传抑制剂方面的新见解。